WEHI scientists find hidden cell death defect behind IBD relapses — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- WEHI researchers identified a "smoldering" molecular defect in intestinal cells of IBD patients, finding cells remained primed to die even when patients felt well and their disease appeared clinically controlled.
- The study analyzed ~900 gut biopsies from 80 people with and without IBD, plus patient-derived organoids ("mini-intestines"), challenging the long-held assumption that cell death in IBD is merely a consequence of inflammation.
- Patients were tracked for more than two years, and those showing stronger intestinal cell death signaling were more likely to experience a relapse, suggesting the defect has predictive value.
- The defect was detectable at the earliest stages of disease activity, including in patients with clinically mild IBD, prompting researchers to call it "one of the first dominoes to fall."
- Study co-author Dr. Andre Samson said: "Even if you become symptom-free on the current treatments, we know there's a likelihood you're going to have a flare or relapse... there's still this persistent problem sitting there."
- Published in Science, the work could eventually enable more precise molecular monitoring and treatment tailored to individual disease biology — though researchers cautioned a diagnostic test or therapy is not imminent.
Why it matters: IBD affects roughly 180,000 Australians and an estimated millions worldwide, with patients cycling between remission and sudden, severe flare-ups that often require hospitalization. By showing that a cell-death defect lingers invisibly during remission and correlates with relapse risk over two years of follow-up, the study reframes cell death from collateral damage into a potential driver of disease — opening a path toward molecular monitoring tools that flag relapse before symptoms appear.
Ask SkimNews
